Key result
Concomitant deletion of adipocyte Jak2 in hepatocyte Jak2-deficient mice prevented the spontaneous development of insulin resistance, metabolic liver disease, and hepatocellular carcinoma.
Why the study?
Loss of growth hormone signaling reportedly predisposes to NAFLD and NASH via direct actions on the liver, but the role of specific tissue signaling mechanisms remained to be clarified.
Adipocyte JAK2 mediates growth hormone-induced metabolic liver disease and carcinogenesis, suggesting adipocyte GH signaling as a potential therapeutic target.
Adipocyte Jak2 emerges as a key driver in this model; leaves open human therapeutic targeting pending clinical studies.
Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are liver manifestations of the metabolic syndrome and can progress to hepatocellular carcinoma (HCC). Loss of Growth Hormone (GH) signaling is reported to predispose to NAFLD and NASH through direct actions on the liver. Here, we report that aged mice lacking hepatocyte Jak2 (JAK2L), an obligate transducer of Growth Hormone (GH) signaling, spontaneously develop the full spectrum of phenotypes found in patients with metabolic liver disease, beginning with insulin resistance and lipodystrophy and manifesting as NAFLD, NASH and even HCC, independent of dietary intervention. Remarkably, insulin resistance, metabolic liver disease, and carcinogenesis are prevented in JAK2L mice via concomitant deletion of adipocyte Jak2 (JAK2LA). Further, we demonstrate that GH increases hepatic lipid burden but does so indirectly via signaling through adipocyte JAK2. Collectively, these data establish adipocytes as the mediator of GH-induced metabolic liver disease and carcinogenesis. In addition, we report a new spontaneous model of NAFLD, NASH, and HCC that recapitulates the natural sequelae of human insulin resistance-associated disease progression. The work presented here suggests a attention be paid towards inhibition of adipocyte GH signaling as a therapeutic target of metabolic liver disease.
No takes yet. Share an insight, caveat, or question.
Corbit et al. (2019) studied Non-alcoholic fatty liver disease (NAFLD), NASH, and hepatocellular carcinoma (HCC). Concomitant deletion of adipocyte Jak2 (JAK2LA) vs. Mice lacking only hepatocyte Jak2 (JAK2L) was evaluated on Insulin resistance, metabolic liver disease, and carcinogenesis. Concomitant deletion of adipocyte Jak2 in hepatocyte Jak2-deficient mice prevented the spontaneous development of insulin resistance, metabolic liver disease, and hepatocellular carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: